From: Biogenesis, cellular effects, and biomarker value of circHIPK3
Roles | Cancers | miRNA | mRNA/protein | Function | Refs. |
---|---|---|---|---|---|
Tumor promotor | Non-small cell lng cancer | miR124-3p | SphK1, CDK4 | Proliferation | [94] |
STAT3-PRKAA/AMPKalpha | Proliferation, migration, invasion, autophagy | [13] | |||
miR-149 | FOXM1 | growth, apoptosis, migration, invasion | [53] | ||
miR-379 | IGF1 | Proliferation | [73] | ||
Colorectal cancer | miR-637 | STAT3/Bcl-2/beclin1 | Autophagy, oxaliplatin-resistance | [100] | |
miR-7 | FAK, IGF1R, EGFR, YY1 | Proliferation, migration, invasion, apoptosis | [95] | ||
miR-1207-5p | FMNL2 | Proliferation, migration, invasion | [91] | ||
Cervical cancer | miR-338-3p | HIF-1 | Growth, metastasis, EMT | [63] | |
Gallbladder cancer | miR-124 | ROCK1-CDK6 | Proliferation, apoptosis | [33] | |
Glioma | miR-124-3p | STAT3, WEEE1 | Proliferation, invasion, EMT | [47, 85] | |
CCND2 | Proliferation, invasion | ||||
miR-654 | IGF2BP3 | Proliferation, invasion, tumor propagation | [31] | ||
miR-421 | ZIC5 | Invasion, apoptosis temozolomide (TMZ) resistance | [24, 25] | ||
miR-524-5p | KIF2A | Apoptosis, proliferation, metastasis, Temozolomide resistance | [93] | ||
Prostate cancer | miR338-3p | Cdc25B/Cdc2 | G2/M transition, proliferation, apoptosis | [45] | |
ADAM17 | Proliferative, invasive | [6] | |||
miR-193a-3p | MCL1 | Proliferation, migration, invasion | [10] | ||
Oral squamous cell carcinoma | miR-124 | Proliferation | [77] | ||
miR-381-3p | YAP1 | Proliferation, invasion, migration, apoptosis | [4] | ||
Nasopharyngeal carcinoma | miR-4288 | ELF3 | Proliferation, migration, invasion | [34] | |
Hepatocellular carcinoma | miR124 | AQP3 | Proliferation, migration | [12] | |
miR-582-3p | AQP3 | Proliferation, migration, invasion, apoptosis | [97] | ||
Pancreatic cancer | miR-330-5p | RASSF1 | Proliferation, invasive, migration, apoptosis, promotes Gemcitabine Resistance | [52] | |
Breast cancer | miR-193a | HMGB1-PI3K-AKT | Proliferation, migration, invasion | [15] | |
Trastuzumab resistance | [98] | ||||
Chronic myeloid leukemia | [21] | ||||
Tumor suppressor | Bladder cancer | miR-558 | HPSE | Migration, invasion, angiogenesis | [41] |
Attenuate gemcitabine resistance | [87] |